DPP4 and obesity due to melanocortin 4 receptor deficiency: There are more patients taking oral anti-diabetic agents including metformin, dipeptidyl peptidase IV inhibitor (DPP4 inhibitor) and sodium-glucose co-transporter 2 inhibitor (SGLT2i) in the obesity group.